Effect of Treatment on Activation of Platelets and Coagulation on TF-Coated Coverslips
| TF . | βTG (μg/L) . | T-AT (μg/L) . | FPA (μg/L) . |
|---|---|---|---|
| Placebo | 709 ± 111 | 175 ± 21 | 334 ± 51 |
| Aspirin | 657 ± 97 | 182 ± 25 | 292 ± 68 |
| Ticlopidine | 512 ± 86 | 179 ± 14 | 283 ± 56 |
| Aspirin + ticlopidine | 497 ± 55 | 154 ± 15 | 283 ± 63 |
| TF . | βTG (μg/L) . | T-AT (μg/L) . | FPA (μg/L) . |
|---|---|---|---|
| Placebo | 709 ± 111 | 175 ± 21 | 334 ± 51 |
| Aspirin | 657 ± 97 | 182 ± 25 | 292 ± 68 |
| Ticlopidine | 512 ± 86 | 179 ± 14 | 283 ± 56 |
| Aspirin + ticlopidine | 497 ± 55 | 154 ± 15 | 283 ± 63 |
Nonanticoagulated human blood was perfused over TF-coated coverslips for 3 minutes at a shear rate of 2,600 s−1. Markers of activation of platelets (βTG) and coagulation (TAT, FPA) were measured in blood collected at the flow outlet of the chamber between 2.5 and 3 minutes perfusion.